BMRN moved below its 50-day moving average on September 22, 2026 date and that indicates a change from an upward trend to a downward trend. In 36 of 49 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 73%.
The Momentum Indicator moved below the 0 level on September 15, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BMRN as a result. In 55 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 65%.
The 10-day moving average for BMRN crossed bearishly below the 50-day moving average on September 25, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 72%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BMRN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 60%.
The Aroon Indicator for BMRN entered a downward trend on October 15, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where BMRN's RSI Oscillator exited the oversold zone, 20 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 67%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 20 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +3.07% 3-day Advance, the price is estimated to grow further. Considering data from situations where BMRN advanced for three days, in 166 of 282 cases, the price rose further within the following month. The odds of a continued upward trend are 59%.
BMRN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is 2 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating steady price growth. BMRN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 89 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 93 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.821) is normal, around the industry mean (26.782). P/E Ratio (160.703) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.348) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (3.727) is also within normal values, averaging (437.542).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BMRN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The RSI Oscillator for MIRM moved out of oversold territory on October 09, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 15 similar instances when the indicator left oversold territory. In 14 of the 15 cases the stock moved higher. This puts the odds of a move higher at 90%.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The Moving Average Convergence Divergence (MACD) for MIRM just turned positive on October 12, 2026. Looking at past instances where MIRM's MACD turned positive, the stock continued to rise in 41 of 48 cases over the following month. The odds of a continued upward trend are 85%.
Following a +3.48% 3-day Advance, the price is estimated to grow further. Considering data from situations where MIRM advanced for three days, in 235 of 311 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
MIRM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on September 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MIRM as a result. In 59 of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 61%.
The 50-day moving average for MIRM moved below the 200-day moving average on October 02, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MIRM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 64%.
The Aroon Indicator for MIRM entered a downward trend on October 15, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Profit vs. Risk Rating rating for this company is 36 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating steady price growth. MIRM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 69 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (26.596) is normal, around the industry mean (26.782). P/E Ratio (0.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (8.842) is also within normal values, averaging (437.542).
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
BMRN | MIRM | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 59 | 71 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 93 Overvalued | 69 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 36 | |
SMR RATING 1..100 | 89 | 100 | |
PRICE GROWTH RATING 1..100 | 61 | 64 | |
P/E GROWTH RATING 1..100 | 2 | 100 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
MIRM's Valuation (69) in the null industry is in the same range as BMRN (93) in the Biotechnology industry. This means that MIRM’s stock grew similarly to BMRN’s over the last 12 months.
MIRM's Profit vs Risk Rating (36) in the null industry is somewhat better than the same rating for BMRN (100) in the Biotechnology industry. This means that MIRM’s stock grew somewhat faster than BMRN’s over the last 12 months.
BMRN's SMR Rating (89) in the Biotechnology industry is in the same range as MIRM (100) in the null industry. This means that BMRN’s stock grew similarly to MIRM’s over the last 12 months.
BMRN's Price Growth Rating (61) in the Biotechnology industry is in the same range as MIRM (64) in the null industry. This means that BMRN’s stock grew similarly to MIRM’s over the last 12 months.
BMRN's P/E Growth Rating (2) in the Biotechnology industry is significantly better than the same rating for MIRM (100) in the null industry. This means that BMRN’s stock grew significantly faster than MIRM’s over the last 12 months.
| BMRN | MIRM | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 67% | 1 day ago 90% |
| Stochastic ODDS (%) | 1 day ago 72% | 1 day ago 90% |
| Momentum ODDS (%) | 1 day ago 65% | 3 days ago 61% |
| MACD ODDS (%) | N/A | 1 day ago 85% |
| TrendWeek ODDS (%) | 1 day ago 60% | 1 day ago 81% |
| TrendMonth ODDS (%) | 1 day ago 63% | 1 day ago 67% |
| Advances ODDS (%) | 1 day ago 59% | 1 day ago 76% |
| Declines ODDS (%) | 7 days ago 60% | 10 days ago 64% |
| BollingerBands ODDS (%) | 1 day ago 70% | 1 day ago 78% |
| Aroon ODDS (%) | 1 day ago 65% | 1 day ago 57% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BMRN’s FA Score shows that 1 FA rating(s) are green while MIRM’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BMRN’s TA Score shows that 4 TA indicator(s) are bullish while MIRM’s TA Score has 5 bullish TA indicator(s).
BMRN (@Biotechnology) experienced а +2.11% price change this week, while MIRM (@Biotechnology) price change was +1.28% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -5.57%. For the same industry, the average monthly price growth was -12.13%, and the average quarterly price growth was -18.10%.
BMRN is expected to report earnings on Nov 03, 2026.
MIRM is expected to report earnings on Nov 17, 2026.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| VMO | 8.71 | 0.14 | +1.63% |
| Invesco Municipal Opportunity Trust | |||
| MMSC | 26.09 | 0.38 | +1.46% |
| First Trust Multi-Manager Small Cap Opportunities ETF (MMSC) | |||
| DIHP | 34.10 | 0.34 | +1.01% |
| Dimensional International High Profitability ETF (DIHP) | |||
| ADPV | 43.71 | 0.33 | +0.77% |
| Adaptiv Select ETF (ADPV) | |||
| RND | 33.74 | 0.09 | +0.26% |
| First Trust Bloomberg R&D Leaders ETF (RND) | |||
A.I.dvisor indicates that over the last year, MIRM has been loosely correlated with XERS. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if MIRM jumps, then XERS could also see price increases.
| Ticker / NAME | Correlation To MIRM | 1D Price Change % | ||
|---|---|---|---|---|
| MIRM | 100% | +3.04% | ||
| XERS - MIRM | 45% Loosely correlated | +3.07% | ||
| KURA - MIRM | 43% Loosely correlated | +0.94% | ||
| EXEL - MIRM | 42% Loosely correlated | +3.02% | ||
| PTCT - MIRM | 41% Loosely correlated | +2.21% | ||
| ORKA - MIRM | 40% Loosely correlated | -3.66% | ||
More | ||||